The association between lactate to albumin ratio and outcomes at early phase in patients with traumatic brain injury.

BACKGROUND: The majority of traumatic brain injury (TBI) cases result in death in the early phase; predicting short-term progno-sis of affected patients is necessary to prevent this. This study aimed to examine the association between the lactate-to-albumin ratio (LAR) on admission and outcomes in the early phase of TBI. METHODS: This retrospective observational study included patients with TBI who visited our emergency department between January 2018 and December 2020. TBI was considered as an head abbreviated injury scale (AIS) score of 3 or higher and other AIS of 2 or lower. The primary and secondary outcomes were 24-h mortality and massive transfusion (MT), respectively. RESULTS: In total, 460 patients were included. The 24-h mortality was 12.6% (n=28) and MT was performed in 31 (6.7%) patients. In the multivariable analysis, LAR was associated with 24-h mortality (odds ratio [OR], 2.021; 95% confidence interval [CI], 1.301-3.139) and MT (OR, 1.898; 95% CI, 1.288-2.797). The areas under the curve of LAR for 24-h mortality and MT were 0.805 (95% CI, 0.766-0.841) and 0.735 (95% CI, 0.693-0.775), respectively. CONCLUSION: LAR was associated with early-phase outcomes in patients with TBI, including 24-h mortality and MT. LAR may help predict these outcomes within 24 h in patients with TBI.

Association between pre-hospital National Early Warning Score and in-hospital mortality in patients with traumatic brain injury.

BACKGROUND: This study aimed to examine the association between the outcome of traumatic brain injury (TBI) and pre-hospital National Early Warning Score (NEWS), Injury Severity Score (ISS), and Revised Trauma Score (RTS). METHODS: This retrospective and observational study included adult patients with TBI admitted to the pre-hospital emergency medical services system between January 2019 and December 2020. TBI was considered when the abbreviated injury scale score was 3 or higher. The primary outcome was in-hospital mortality. RESULTS: Among 248 patients included in the study, in-hospital mortality was 18.5% (n=46). In the multivariate analysis for predict-ing in-hospital mortality, pre-hospital NEWS (Odds ratio [OR], 1.198; 95% Confidence interval [CI], 1.042-1.378) and RTS (OR, 0.568; 95% CI, 0.422-0.766) were independently associated with in-hospital mortality. The area under the curves (AUCs) for ISS, RTS, and pre-hospital NEWS were 0.731 (95% CI, 0.672-0.786), 0.853 (95% CI, 0.802-0.894), and 0.843 (95% CI, 0.791-0.886), respectively. The AUC of pre-hospital NEWS was significantly different from that of ISS but not from that of RTS. CONCLUSION: Pre-hospital NEWS could contribute to improving prognosis by aiding in the rapid classification of patients with TBI in the field and their transportation to appropriate hospitals.

Swallowing Outcomes Following Voice Therapy in Multiple System Atrophy with Dysphagia: Comparison of Treatment Efficacy with Parkinson's Disease.

Difficulties with speech and swallowing occur in patients with Parkinsonism. Lee Silverman Voice Treatment (LSVT) is proven as an effective treatment for speech and swallowing function in idiopathic Parkinson's disease (IPD). The effect of LSVT on swallowing function in multiple system atrophy-cerebellar type (MSA-C) is unknown. We sought to determine LSVT's effect on swallowing function in MSA-C patients compared to IPD patients. LSVT-LOUD was performed on 13 patients with Parkinsonism (6 IPD and 7 MSA-C). Maximum phonation time (MPT), voice intensity, Speech Handicap Index-15 (SHI-15), Swallowing-Quality of Life (SWAL-QOL), National Institutes of Health-swallowing safety scale (NIH-SSS), and videofluoroscopic dysphagia scale (VDS) before and after LSVT were analyzed and reevaluated three months after treatment. The IPD and MSA-C groups showed significant improvements in overall speech and swallowing measures after LSVT. In particular, pharyngeal phase score and total score of VDS improved significantly in both groups. A two-way repeated-measure ANOVA revealed a significant main effect for time in the MPT, voice intensity, NIH-SSS, pharyngeal phase score and total score of VDS, psychosocial subdomain of SHI-15, and SWAL-QOL. The MSA-C group experienced less overall improvement in swallowing function, but the two groups had an analogous pattern of improvement. In conclusion, LSVT is effective for enhancing swallowing function, particularly in the pharyngeal phase, in both IPD and MSA-C patients. This study demonstrated that LSVT elicits significant improvements in MSA-C patients. We deemed LSVT to be an effective treatment for IPD and MSA-C patients who suffer from dysphagia.

Postoperative changes in the pharyngeal airway space through computed tomography evaluation after mandibular setback surgery in skeletal class III patients: 1-year follow-up.

BACKGROUND: This study evaluated the pharyngeal airway space changes up to 1 year after bilateral sagittal split osteotomy mandibular setback surgery and bimaxillary surgery with maxillary posterior impaction through three-dimensional computed tomography analysis. METHODS: A total of 37 patients diagnosed with skeletal class III malocclusion underwent bilateral sagittal split osteotomy setback surgery only (group 1, n = 23) or bimaxillary surgery with posterior impaction (group 2, n = 14). Cone-beam computed tomography scans were taken before surgery (T0), 2 months after surgery (T1), 6 months after surgery (T2), and 1 year after surgery (T3). The nasopharynx (Nph), oropharynx (Oph), hypopharynx (Hph) volume, and anteroposterior distance were measured through the InVivo Dental Application version 5. RESULTS: In group 1, Oph AP, Oph volume, Hph volume, and whole pharynx volume were significantly decreased after the surgery (T1) and maintained. In group 2, Oph volume and whole pharynx volume were decreased (T2) and relapsed at 1 year postoperatively (T3). CONCLUSION: In class III malocclusion patients, mandibular setback surgery only showed a greater reduction in pharyngeal airway than bimaxillary surgery at 1 year postoperatively, and bimaxillary surgery was more stable in terms of airway. Therefore, it is important to evaluate the airway before surgery and include it in the surgical plan.

Relationship between cancer stigma, social support, coping strategies and psychosocial adjustment among breast cancer survivors.

AIMS AND OBJECTIVES: The purpose of this study was to examine the magnitude of cancer stigma, social support, coping strategies and psychosocial adjustment among breast cancer survivors and to identify the factors associated with patients' psychosocial adjustment. BACKGROUND: Few studies have examined the association between cancer stigma and adaptation outcomes, which are considered interpersonal stressors for breast cancer survivors. DESIGN: A correlational, cross-sectional research design was used. METHODS: This study was designed based on the stress-coping theory of Lazarus and Folkman. This descriptive cross-sectional study included 158 breast cancer survivors who visited a Korean tertiary hospital. Data collection was performed using a structured questionnaire and electronic medical records between March-May 2018. Data analyses included descriptive statistics, independent t test, one-way ANOVA, Kruskal-Wallis test, partial correlation analysis and hierarchical regression analysis and were performed with the SPSS WIN 25.0 program. This study adheres to STROBE guidelines. RESULTS: Cancer stigma had the strongest association with psychosocial adjustment among Korean breast cancer survivors, followed by social support and coping strategies. These variables accounted for approximately 44% of the variance in psychosocial adjustment. CONCLUSION: Cancer stigma had the strongest association with psychosocial adjustment. Healthcare professionals should assess patients' cancer stigma to develop patient-tailored stigma management programmes. RELEVANCE TO CLINICAL PRACTICE: Interventions to alleviate cancer stigma should be developed, and social support and coping strategies for breast cancer survivors should be considered in clinical oncology settings.

Regenerative effect of recombinant human bone morphogenetic protein-2/absorbable collagen sponge (rhBMP-2/ACS) after sequestrectomy of medication-related osteonecrosis of the jaw (MRONJ).

OBJECTIVES: Beyond the original application approved by the U.S. Food and Drug Administration, recombinant human bone morphogenetic protein-2 (rhBMP-2) is used for medication-related osteonecrosis of the jaw (MRONJ) treatment because of its bone remodeling enhancement properties. The purpose of the study was to investigate the bone formation effect of rhBMP-2/absorbable collagen sponge (ACS) in patients with MRONJ. MATERIALS AND METHODS: In this retrospective cohort study, 26 female patients diagnosed with MRONJ and who underwent mandibular sequestrectomy at Ajou University Dental Hospital from 2010 to 2018 were included. The experimental group was composed of 18 patients who received rhBMP-2/ACS after sequestrectomy, while the control group was composed of 8 patients who did not receive rhBMP-2/ACS after sequestrectomy. A total dose of 0.5 mg of rhBMP-2 was used in the experimental group at a concentration of 0.5 mg/mL. Follow-up panoramic X-rays were taken immediately after the surgery and more than 6 months after the surgery. Using those X-rays, a radiographic index of bone defect area was calculated using the modified Ihan Hren method, which measures radiographic density of the normal bone and the defect site. RESULTS: This study suggests that rhBMP-2 contributes to new bone formation. The mean radiographic index immediately after surgery and more than 6 months after the surgery for the experimental group was 68.4% and 79.8%, respectively. The mean radiographic index immediately after surgery and more than 6 months after the surgery for the control group was 73.4% and 76.7%, respectively (Wilcoxon signed rank test, P>0.05). The mean radiographic index increased 11.4% in the experimental group and 3.27% in the control group (Mann-Whitney U-test, P <0.05). CONCLUSION: Based on the results, use of rhBMP-2/ACS on bone defect sites after sequestrectomy could be a successful strategy for treatment of MRONJ patients.